What are the considerations for using Suboxone (buprenorphine) and Adderall (amphetamine and dextroamphetamine) together in a patient with opioid use disorder and Attention Deficit Hyperactivity Disorder (ADHD)?

Combining Suboxone and Adderall: Safety and Efficacy

Patients with opioid use disorder (OUD) on buprenorphine (Suboxone) who have co-occurring ADHD should receive stimulant treatment with Adderall when indicated, as this combination improves buprenorphine retention and reduces opioid-related hospitalizations without increasing safety risks. 1, 2

Evidence Supporting Combination Therapy

The most recent and highest quality evidence demonstrates clear benefits of this combination:

• A 2025 study of 10,712 patients with comorbid ADHD and OUD found that those receiving psychostimulants while on buprenorphine had 33% lower odds of buprenorphine discontinuation (OR=0.669) and 51% lower odds of opioid-related hospitalization (OR=0.493). 1

• Each additional psychostimulant prescription fill was associated with a 42% lower incidence rate of hospitalization (IRR=0.580), suggesting a dose-response relationship favoring treatment. 1

• A 2023 analysis of 90,269 patients confirmed improved buprenorphine retention in both those with (aHR=0.91) and without (aHR=0.92) concurrent psychostimulant use disorder when prescribed amphetamines. 2

Treatment Algorithm

Step 1: Confirm Diagnoses and Assess Severity

• Verify OUD diagnosis using DSM-5 criteria (at least 2 criteria within 12 months). 3
• Confirm ADHD diagnosis through comprehensive evaluation, recognizing that ADHD symptoms are highly prevalent (19.4%) in patients with heroin dependence. 4
• Screen for adult ADHD using validated tools like the Adult ADHD Self-Report Scale (ASRS-v1.1). 4

Step 2: Initiate or Optimize Buprenorphine First

• Establish stable buprenorphine maintenance therapy before adding stimulants, as medication-assisted treatment with buprenorphine is the evidence-based standard for OUD. 3, 5
• Buprenorphine/naloxone is preferred over buprenorphine alone due to abuse-deterrent properties. 6
• For patients with complex persistent opioid dependence failing to benefit from high opioid doses, buprenorphine/naloxone may be safer than high-dose mu agonists. 6

Step 3: Add Stimulant Medication for ADHD

Preferred approach:

• Start with long-acting amphetamine formulations (Adderall XR or lisdexamfetamine) to minimize abuse potential and improve adherence. 7
• Initial dosing: Adderall XR 10 mg once daily in the morning. 8
• Titrate by 5-10 mg weekly based on response, up to typical adult doses of 20-40 mg daily (maximum 50 mg). 8, 7

Alternative if amphetamines are contraindicated:

• Extended-release methylphenidate formulations have demonstrated safety in patients on opioid substitution therapy. 9
• Atomoxetine (60-100 mg daily) is an uncontrolled substance with lower abuse potential, though it requires 2-4 weeks for full effect and has less robust efficacy than stimulants. 7, 9

Step 4: Implement Enhanced Monitoring

Critical monitoring parameters:

• Weekly contact during stimulant titration, then monthly follow-up during maintenance. 7
• Regular urine drug screening to ensure compliance and detect illicit substance use. 10
• Blood pressure and pulse at baseline and each visit. 7
• Assessment for emergence of new psychiatric symptoms or worsening of existing conditions. 7
• Monitor for signs of stimulant misuse or diversion (though evidence shows this is uncommon with proper monitoring). 10

Step 5: Address Comorbid Psychiatric Conditions

• If depressive symptoms persist despite ADHD treatment, add an SSRI (fluoxetine or sertraline) to the regimen, as there are no significant drug-drug interactions between stimulants and SSRIs. 7
• Avoid benzodiazepines for anxiety, as they can potentiate CNS depression with buprenorphine and may reduce self-control. 3, 7
• For anxiety, consider SSRIs or alpha-2 agonists (guanfacine 1-4 mg daily) as adjuncts. 7

Safety Considerations and Drug Interactions

No major pharmacokinetic interactions exist between buprenorphine and amphetamines:

• Studies of buprenorphine with methadone substitution therapy showed no clinically significant interactions requiring dose adjustments. 11
• The combination has not been associated with increased acute SUD-related events or drug-related poisonings. 2

Absolute contraindications:

• Never use MAO inhibitors concurrently with stimulants due to risk of hypertensive crisis; allow at least 14 days between discontinuation of MAOIs and stimulant initiation. 7
• Avoid stimulants in patients with uncontrolled hypertension or symptomatic cardiovascular disease. 7

Common Pitfalls to Avoid

• Do not withhold stimulant treatment solely based on OUD diagnosis or active buprenorphine therapy. The evidence clearly demonstrates safety and improved outcomes with combination therapy. 1, 2

• Do not assume that treating ADHD will worsen substance use. Patients with greater ADHD symptom severity have worse employment outcomes and higher rates of psychiatric comorbidity, making treatment essential. 4

• Do not use immediate-release stimulant formulations as first-line in this population. Long-acting formulations reduce abuse potential and improve adherence. 7, 9

• Do not prescribe stimulants without adequate monitoring infrastructure. This population requires close follow-up with urine drug screening and psychiatric assessment. 10

• Do not discontinue buprenorphine to simplify the regimen. Patients with OUD are unlikely to tolerate abstinence and are at heightened risk for using hazardous substitutes. 6

Special Populations and Considerations

Patients on methadone:

• Those on methadone have higher rates of ADHD symptoms compared to buprenorphine (19.4% overall prevalence). 4
• Particular care is required when transitioning from methadone to buprenorphine due to risk of severe precipitated withdrawal. 12

Patients with concurrent psychostimulant use disorder:

• Even in patients with active cocaine or methamphetamine use, prescription amphetamines improved buprenorphine retention without increasing acute adverse events. 2
• Enhanced monitoring and psychosocial interventions are warranted but should not preclude treatment. 9

Patients with lower education or unemployment:

• These individuals are more likely to have severe ADHD symptoms and represent a high-need population requiring comprehensive treatment including both medications. 4

Psychosocial Interventions

While pharmacotherapy is essential, combine with:

• Cognitive-behavioral therapy targeting both ADHD and substance use. 5
• Contingency management and relapse prevention strategies. 5
• Harm reduction counseling including overdose prevention education and naloxone distribution. 12
• Skills training for ADHD-related functional impairments. 8